menu
    • menu
    [{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ERYTHROPOIETIN","moa":"Erythropoietin receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Australian and New Zealand Intensive Care Research Centre","sponsor":"University College Dublin | Medical Research Institute of New Zealand | Medical Research Future Fund | Health Research Board, Ireland | Health Research Council NZ | Irish Critical Care Clinical Trials Network | ANZICS Clinical Trials Group | Monash Univer","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ERYTHROPOIETIN","moa":"Erythropoietin receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Australian and New Zealand Intensive Care Research Centre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Australian and New Zealand Intensive Care Research Centre \/ University College Dublin | Medical Research Institute of New Zealand | Medical Research Future Fund | Health Research Board, Ireland | Health Research Council NZ | Irish Critical Care Clinical Trials Network | ANZICS Clinical Trials Group | Monash Univer","highestDevelopmentStatusID":"10","companyTruncated":"Australian and New Zealand Intensive Care Research Centre \/ University College Dublin | Medical Research Institute of New Zealand | Medical Research Future Fund | Health Research Board, Ireland | Health Research Council NZ | Irish Critical Care Clinical Trials Network | ANZICS Clinical Trials Group | Monash Univer"},{"orgOrder":0,"company":"Megalabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"BRAZIL","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"ERYTHROPOIETIN","moa":"Erythropoietin receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Megalabs","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Megalabs \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Megalabs \/ Undisclosed"},{"orgOrder":0,"company":"Blau Farmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SPAIN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"ERYTHROPOIETIN","moa":"Erythropoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Blau Farmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blau Farmaceutica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Blau Farmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Megalabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BRAZIL","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ERYTHROPOIETIN","moa":"Erythropoietin receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Megalabs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Megalabs \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Megalabs \/ Undisclosed"},{"orgOrder":0,"company":"Angde Biotech Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ERYTHROPOIETIN","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Angde Biotech Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Angde Biotech Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Angde Biotech Pharmaceutical \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for ERYTHROPOIETIN

    Menu

    ERYTHROPOIETIN

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Megalabs

                            Brazil arrow
                            PREP
                            Not Confirmed

                            Megalabs

                            Brazil arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparative Study of Two Recombinant Human Erythropoietin Products in Chronic Kidney Disease Patients

                            Details : Epoetin Alfa is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia-associated with Renal Insufficiency, Chronic.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            April 08, 2024

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Blau Farmaceutica

                            Brazil arrow
                            PREP
                            Not Confirmed

                            Blau Farmaceutica

                            Brazil arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Asses the Impact of Early Starting Erythropoetin in the Reduction of Transfusions Blood in Childrens

                            Details : Erythropoietin is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 30, 2023

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Angde Biotech Pharmaceutical

                            Country arrow
                            PREP
                            Not Confirmed

                            Angde Biotech Pharmaceutical

                            Country arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of PEG-EPO Injection (CHO Cells) for Maintenance Therapy of Patients With Renal Anemia .

                            Details : Recombinant Human Erythropoietin is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Anemia, Renal.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            November 29, 2022

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Megalabs

                            Brazil arrow
                            PREP
                            Not Confirmed

                            Megalabs

                            Brazil arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Biosimilarity Study of Intravenous Recombinant Human Erythropoietin in Healthy Volunteers

                            Details : Erythropoietin is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            July 08, 2021

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Australian and New Zealand Intensive Care Research Centre

                            Country arrow
                            PREP
                            Not Confirmed

                            Australian and New Zealand Intensive Care Research Centre

                            Country arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase III

                            Sponsor : University College Dublin | Medical Research Institute of New Zealand | Medical Research Future Fund | Health Research Board, Ireland | Health Research Council NZ | Irish Critical Care Clinical Trials Network | ANZICS Clinical Trials Group | Monash Univer

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients

                            Details : Epoetin Alfa is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Wounds and Injuries.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 19, 2020

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase III

                            Sponsor : University College Dublin | Medical Research Institute of New Zealand | Medical Research Future Fund | Health Research Board, Ireland | Health Research Council NZ | Irish Critical Care Clinical Trials Network | ANZICS Clinical Trials Group | Monash Univer

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Zydus Lifesciences

                            India arrow
                            PREP
                            Not Confirmed

                            Zydus Lifesciences

                            India arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Desidustat in the Treatment of Anemia in CKD on Dialysis Patients

                            Details : Epoetin Alfa is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Renal Insufficiency, Chronic.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 02, 2020

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sports Medicine Research and Testing Laboratory

                            Country arrow
                            PREP
                            Not Confirmed

                            Sports Medicine Research and Testing Laboratory

                            Country arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CD71 in Dried Blood Spots in Healthy Males

                            Details : Epoetin Alfa is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 29, 2019

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Bio Sidus

                            Country arrow
                            PREP
                            Not Confirmed

                            Bio Sidus

                            Country arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volun...

                            Details : Epoetin Alfa is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Anemia.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 30, 2019

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Azidus

                            Brazil arrow
                            PREP
                            Not Confirmed

                            Azidus

                            Brazil arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Sponsor : Blau Farmaceutica

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects.

                            Details : Erythropoietin is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Renal Insufficiency, Chronic.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            June 28, 2018

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Sponsor : Blau Farmaceutica

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Dong-A ST Co., Ltd.

                            South Korea arrow
                            PREP
                            Not Confirmed

                            Dong-A ST Co., Ltd.

                            South Korea arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            To Evaluate the Efficacy, Safety, and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex)

                            Details : Eporon (Epoetin Alfa) is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia-associated with Renal Insufficiency, Chronic.

                            Product Name : Eporon

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            May 11, 2018

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth